Background: Remote monitoring of implantable cardioverter-defibrillators has been
| INTRODUCTION
The survival of patients at high risk of sudden cardiac arrest can be improved with the use of implantable cardioverter-defibrillators (ICDs). 1 The long-term mortality and morbidity of patients who receive ICDs remain substantial, however. In addition to the physician visits needed to manage disease-related morbidity, current guidelines recommend that patients with ICDs should be evaluated every 3 to 6 months to assess device function. 2 This regimen can impose a considerable burden on both patients and physicians if patients must be evaluated in the office. As a consequence, device follow-up is not reliable in routine clinical practice, with nearly one-quarter of patients not seen in-person within a year of device implantation. 3 Remote patient monitoring (RPM) has been promoted as a strategy to reduce this burden. It can improve the efficiency of care delivery by replacing at least some in-office visits with remote monitoring transmissions [4] [5] [6] [7] without compromising safety. [7] [8] [9] Remote monitoring may also improve patient satisfaction and quality of life as it entails less travel time, time off work, and interruption of patient activities. Data suggests that clinically actionable events are detected sooner with remote monitoring than with standard in-office follow-up, 10 potentially allowing clinicians to act on these issues before they cause increased morbidity, hospitalizations, and costs. RPM also provides a convenient means for regular assessment of device-related parameters, such as lead impedance and battery status, which may allow early detection of a device and lead malfunction. [11] [12] [13] [14] [15] RPM can, therefore, enhance device safety and potentially improve clinical outcomes. 10, [16] [17] [18] [19] [20] RPM was associated with lower hospitalization rates and reduced mortality in the large, real-world PREDICT RM study, 21 and its routine use has been endorsed by professional societies. 22 However, while RPM is widely available, it is still not universally utilized by clinicians. In a recent U.S. study, fewer than half of ICD recipients enrolled in and activated RPM, 21 and utilization is significantly lower in Europe. To determine whether RPM has economic benefits in addition to the associated clinical benefits and to determine the magnitude of the health and economic incentives for increased use of RPM, we developed an economic model to conduct an analysis of the clinical outcomes and costs of RPM versus no RPM from a Medicare perspective. Previous studies done over limited time horizons have shown RPM to be relatively cost-effective, [23] [24] [25] [26] [27] but this has not been evaluated over a lifelong time horizon.
2 | METHODS
| The PREDICT RM database
This study represents a collaborative effort between Boston Scientific Corporation, the American College of Cardiology Founda- 
| Patient population
The patient population for this study was composed of Medicare patients with RPM-capable devices (N = 15 254; control = 9906; RPM = 5348) taken from the population studied in the PREDICT RM database. Simulated individual-patient profiles were created based on the categorical distributions of patient characteristics in the PREDICT RM database (Table 1) . To reflect the heterogeneity of the real patient population and to better preserve correlations among patient characteristics, the patient population was stratified into subgroups based on the predicted times to rehospitalization and death-the key outcomes of interest. Details of the risk stratification (eTable 1) and patient characteristics for the risk-stratified subgroups (eTable 2) can be found in the Appendix ("Patient
Characteristics by Risk Strata").
| Economic model
An economic model was developed using Microsoft Excel to simulate individual patients using a time-to-event approach to evaluate the 
| Model inputs: Clinical

Parametric survival equations
Kaplan-Meier survival curves were generated for first rehospitalization and death; extrapolation beyond the observation period of the database study was achieved using parametric survival fits to the Kaplan-Meier curves. Construction of the survival curves and the time-to-rehospitalization and time-to-death analyses are described in the Appendix ("Survival Curves for Time-to-rehospitalization and Time-to-death Analysis").
Regression analysis of predictors
The survival fitting yielded distributions for each time-to-event curve for the overall population; the fits were then adjusted to account for individual patient characteristics. Times to first rehospitalization and death were modified based on patient characteristics and, for mortality, history of the first rehospitalization. Model building with predictors is described in detail in the Appendix ("Model Building with Predictors").
Rates of subsequent rehospitalizations
The model accounts for rehospitalization events subsequent to a patient's first rehospitalization using a constant rate. Counts of second and additional rehospitalizations were divided by the duration of follow-up (counting from the time of the first rehospitalization) to give subsequent rehospitalization rates by treatment arm (RPM vs no RPM).
Rates of outpatient claims
The model accounts for three classes of outpatient claims: hospital outpatient claims, ambulatory surgical center (ASC) claims, and physician claims. ASC claims constituted less than 0.6% of the total, however, and so were combined with hospital outpatient claims.
For each type of outpatient claim, rates were calculated separately before and after the first rehospitalization as the number of unique claims per patient divided by the appropriate average time-time to first rehospitalization or time from the first rehospitalization until death. 
| Model inputs: Economic
Costs Each hospitalization event was assigned an average cost based on the distribution of diagnosis-related groups (DRGs) codes in the observed hospitalization events and the associated DRG costs.
Outpatient claim costs were specific to the type of claim, the treatment arm, and whether the claim occurred before or after the first rehospitalization. Additional details regarding the calculation of hospitalization and outpatient claim costs can be found in the Appendix (eTable 3).
Utilities
Utility values for the patients are dependent on a patient's baseline characteristics, comorbidities, and rehospitalization. 30 Patients were assumed to have a utility of 0 for their assigned length of stay during rehospitalization events. The effects of both patient characteristics F I G U R E 1 Overview of the model development process (outpatient claims not shown). The figure illustrates the data sources and inputs used in the economic model, and how the final inputs were derived. Boxes next to or over arrows describe the process completed to map PREDICT RM data to model inputs (eTable 4) and comorbidities (eTable 5) were included in the estimation of patient utility.
| Model validation
To verify that the model would reproduce the observed results upon which the model inputs were based, we simulated two cohorts of patients, one with RPM and one without, and compared the model outputs to the observed data from the PREDICT RM database.
| Sensitivity and scenario analyses
With other studies failing to find an improvement in mortality due to use of RPM, complementary scenario analyses assessed the effects of patient characteristics and the importance of RPM effects on mortality as well as first rehospitalization. One-way deterministic sensitivity analyses were conducted to investigate the sensitivity of model results to uncertainty in the values of input parameters. Additional analyses focused on the results at shorter time horizons, RPM effects on outpatient claim rates and costs, and the effects of assumptions regarding utilities.
3 | RESULTS
| Validation of time-to-event model equations
The fitting of parametric survival functions to the Kaplan-Meier curves resulted in the selection of Weibull functions for both time to first rehospitalization and time to death. Weibull fits were selected F I G U R E 2 Annual outpatient claim rates by risk group. Rates for groups of fewer than 100 patients have been omitted. Lines have been added to show trends. Risk groups created by combinations of categorical rehospitalization and mortality risks are listed sequentially from highest to lowest. A linear trendline was added to illustrate observed trends in the data. For both hospital outpatient and physician claim rates, a similar trend is observed with higher rates for RPM vs no RPM, RPM, remote patient monitoring based on a review of the Akaike and Bayesian information criteria and visual inspection of how well the fits matched the observed data (eTable 6). Extrapolations of the Weibull fits beyond the observed data were evaluated by visual inspection and judged to be clinically plausible (eFigure 1). To verify that the survival curves were properly implemented in the economic model, we compared the survival predicted by the economic model to the survival curves described by the regression equations (eFigure 2). 
| Event rates
Event rates were calculated for rehospitalizations following the first rehospitalization and for all types of outpatient claims. The rate of subsequent rehospitalizations was different in the RPM (1.65 per year) and no-RPM arms (1.79 per year). As with first rehospitalizations, RPM showed a benefit compared to no RPM.
The rates of hospital outpatient/ASC claims and physician claims were consistently higher in the RPM arm than they were in the no-RPM arm. This was true before and after the first rehospitalization, and it was true for the overall population as well as for most of the risk-stratified bins of patients (eTable 7).
We also investigated whether the number of outpatient claims varied by patient risk. We assigned a risk rank to each risk stratum based on the combination of baseline risks of rehospitalization and death (see Appendix (eTable 1)). Plotting the mean outpatient claim rates by risk ranking showed a clear trend toward lower outpatient claim rates in the lower-risk groups (Figure 2 ).
| Cost-effectiveness analysis: Base case
Base-case results are presented in 
| Cost-effectiveness analysis: Scenario and sensitivity analyses
Key scenarios in the analysis were those that removed specific RPM effects from the RPM-arm projections (Table 4) . When the RPM effect on survival was removed, the RPM arm dominated the no-RPM arm (RPM was less costly and more effective). RPM still reduced the number of rehospitalizations, which indirectly reduced mortality. However, without the additional direct RPM effect on mortality, RPM and non-RPM patients enjoyed similar life expectancies, and the additional costs associated with increased longevity were not accrued. When the RPM effect on the risk of the first rehospitalization was removed, the ICER increased 29%. Patients were still living longer with RPM but without the benefit of reduced rehospitalization rates. Results were also examined for each of the different risk strata and key baseline characteristics of interest. The most-severe risk strata (high projected risks of both rehospitalization and death) had much shorter life expectancies than did patients in other risk strata, which resulted in lower incremental QALYs and a higher ICER than in the base case. (eTable 8). Details of these and other scenarios and sensitivity analyses are described in the Appendix ("Scenario and Sensitivity Analysis").
T A B L E 3 Base-case results
Outcome
| DISCUSSION
The clinical utility of remote monitoring in ICD patients is well established and endorsed in the Heart Rhythm Society/European
Heart Rhythm Association (HRS/EHRA) Expert Consensus Statement. 33 However, the cost-effectiveness of remote monitoring is less 2) Although total costs and the number of rehospitalizations are increased due to improved survival, the number of rehospitalizations and overall costs PPY decrease with RPM.
3) With only a direct effect of RPM on the hospitalization rate, RPM becomes a cost-saving strategy that still provides health benefits above that of no-RPM.
4)
The incremental cost-effectiveness ratio for remote monitoring was $10 752 per QALY gained, making RPM "high-value" care by the ACC/American Heart Association (AHA) criterion (<$50 000/ QALY). 34 
5)
These results were robust to various sensitivity and scenario analyses.
Previous cost-effectiveness analyses from small randomized studies have shown RPM to be cost saving or neutral compared with conventional in-office follow-up. 23, 27, 35, 36 Nonhospital costs were generally lower with RPM due to fewer scheduled office visits in the RPM arm (as defined by the protocol). In these studies, the number of unscheduled visits was higher with RPM possibly related to increased detection of arrhythmias and device malfunctions. However, the total number of scheduled plus unscheduled visits was still reduced. In our study, RPM was cost-effective despite an increase in the rate of outpatient claims. In addition to lower visit rates in these previous studies, inpatient costs were also reduced due to fewer hospitalizations and shorter lengths of stays. 35 In addition, device cost savings were seen in the ECOST trial 37 due to improved battery longevity. Had such cost savings been included in our analysis, RPM would have been even more cost-effective.
Clinical equipoise remains regarding the effect of remote monitoring on mortality. Retrospective analysis of two large independent databases 19, 38 both showed an association between RPM utilization and improved survival, with a graded benefit related to the level of adherence to RPM. 38 Results from prospective randomized trials, however, have been mixed. The IN-TIME trial 39 demonstrated a substantial reduction in mortality in the RPM group; however, the rigorous protocol of daily RPM transmissions also resulted in increased direct patient contact. The REM-HF trial 40 did not demonstrate a survival benefit for RPM; however, both arms actually utilized remote monitoring to some extent, as usual care in the control arm could have included remote follow-up every 6 months.
Similarly, no benefit was seen in the MORE-CARE trial, 9 which replaced in-office visits with RPM; however, this trial was not powered to detect mortality differences. As PREDICT RM is a nonrandomized database, it is possible that the observed beneficial effects on hospitalization and mortality could be secondary to confounding factors. Sensitivity analysis was, therefore, performed to evaluate the cost-effectiveness of RPM in the absence of any survival benefit or reduction in hospitalization rate.
When the beneficial effect on rehospitalization was removed, the ICER was still well within the realm of high-value care. When the effect on survival was removed, RPM became a dominant strategy. It continued to have beneficial effects on hospitalizations and was now also cost-saving since there was no increase in survival time during which additional costs would accrue. The cost-effectiveness of RPM was robust across a wide range of sensitivity analyses, with ICERs well below the "high-value care"
threshold of $50,000/QALY in every risk group and in every sensitivity and scenario analysis examined.
| Limitations of study
A key limitation of this study is that it draws primarily from an observational data source. Although this provided a large sample from which to estimate parameters, observational studies may have unobserved confounding factors that cannot be controlled for.
However, estimates for all parameters in this study were controlled for a large set of patient and provider characteristics.
This study did not differentiate Medicare costs for hospitalization or outpatient claims due to cardiac conditions from those associated with other medical conditions. Therefore, the costs associated with RPM include many outpatient claims and hospitalizations unrelated to the intervention. However, as the increased costs leading to an ICER of $10 752/QALY for RPM are due to costs accrued during the extra 9.3 months of survival, the ICER would have been even more favorable if those noncardiac expenses were excluded.
In calculating the costs of hospitalizations, hospital outpatient claims, and physician claims, we used average costs. Although these averages differentiated between RPM and no RPM, it is possible that a more detailed analysis of cost differences in the two groups would lead to different and more informative cost estimates.
Patients were included in the RPM group if only a single transmission was received, but it has been shown that there is a dose-response relationship with RPM. 38 Including patients with only sporadic RPM may underestimate the value of regular remote monitoring.
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The model used extrapolation of first rehospitalization and mortality events to assess a time horizon spanning the patient population's lifetime, For more information, go to CVQuality.ACC.org/NCDR or email ncdrresearch@acc.org.
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